Analysts Set Beigene Ltd (NASDAQ:BGNE) PT at $200.13

Beigene Ltd (NASDAQ:BGNE) has been given an average recommendation of “Buy” by the twelve ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $200.13.

Several brokerages recently issued reports on BGNE. Piper Jaffray Companies lifted their price target on shares of Beigene from $180.00 to $200.00 in a report on Friday, November 1st. ValuEngine lowered shares of Beigene from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 17th. Guggenheim set a $205.00 price target on shares of Beigene and gave the company a “buy” rating in a report on Friday, November 1st. Maxim Group lifted their price target on shares of Beigene from $170.00 to $210.00 and gave the company a “buy” rating in a report on Monday, November 4th. Finally, Cowen reaffirmed a “buy” rating and set a $170.00 price target on shares of Beigene in a report on Wednesday, October 16th.

Shares of NASDAQ BGNE traded up $6.55 during mid-day trading on Thursday, reaching $199.44. 417,900 shares of the company were exchanged, compared to its average volume of 330,028. The stock has a market capitalization of $9.02 billion, a P/E ratio of -16.41 and a beta of 1.00. The company has a quick ratio of 6.28, a current ratio of 6.46 and a debt-to-equity ratio of 0.15. The company’s 50-day simple moving average is $138.52 and its 200-day simple moving average is $131.38. Beigene has a twelve month low of $108.00 and a twelve month high of $200.00.

Beigene (NASDAQ:BGNE) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.01) by $1.58. The company had revenue of $243.35 million for the quarter, compared to analyst estimates of $65.58 million. Beigene had a negative net margin of 153.32% and a negative return on equity of 38.41%. The firm’s revenue was up 360.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.92) EPS. As a group, equities research analysts expect that Beigene will post -11.49 EPS for the current year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In related news, Director Timothy Yung-Cheng Chen sold 3,800 shares of Beigene stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $189.15, for a total transaction of $718,770.00. Following the sale, the director now directly owns 4,000 shares in the company, valued at approximately $756,600. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CMO Jane Huang sold 2,500 shares of Beigene stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $134.74, for a total transaction of $336,850.00. Following the sale, the chief marketing officer now owns 328,873 shares in the company, valued at $44,312,348.02. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 52,676 shares of company stock worth $9,343,855. 13.40% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. Capital Investment Advisory Services LLC acquired a new stake in Beigene during the 2nd quarter worth approximately $26,000. Ladenburg Thalmann Financial Services Inc. lifted its position in shares of Beigene by 24.8% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 443 shares of the company’s stock worth $55,000 after purchasing an additional 88 shares during the period. Riverhead Capital Management LLC lifted its position in shares of Beigene by 28.6% in the 2nd quarter. Riverhead Capital Management LLC now owns 450 shares of the company’s stock worth $56,000 after purchasing an additional 100 shares during the period. Flagship Harbor Advisors LLC acquired a new position in shares of Beigene in the 3rd quarter worth approximately $58,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Beigene by 1,500.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 592 shares of the company’s stock worth $73,000 after purchasing an additional 555 shares during the period.

About Beigene

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Further Reading: What are convertible shares? 

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Leave a Reply

Your email address will not be published. Required fields are marked *

*